Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Accured Expenses: 2022-2025

Historic Change in Accured Expenses for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $708,000.

  • Corvus Pharmaceuticals' Change in Accured Expenses rose 895.51% to $708,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 537.79%. This contributed to the annual value of -$245,000 for FY2024, which is 93.15% up from last year.
  • Corvus Pharmaceuticals' Change in Accured Expenses amounted to $708,000 in Q3 2025, which was down 38.00% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Change in Accured Expenses peaked at $2.2 million during Q3 2022, and registered a low of -$1.9 million during Q1 2023.
  • For the 3-year period, Corvus Pharmaceuticals' Change in Accured Expenses averaged around -$166,091, with its median value being $98,000 (2023).
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Change in Accured Expenses slumped by 401.04% in 2023, and later skyrocketed by 895.51% in 2025.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Change in Accured Expenses stood at -$1.0 million in 2022, then soared by 42.37% to -$589,000 in 2023, then rose by 16.81% to -$490,000 in 2024, then surged by 895.51% to $708,000 in 2025.
  • Its Change in Accured Expenses stands at $708,000 for Q3 2025, versus $1.1 million for Q2 2025 and $146,000 for Q1 2025.